NANOBIOTIX 31.080 € (+3,74 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
TOTALENERGIES 68.360 € (-1,31 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
ADYEN 824.900 € (+0,37 %)
EXAIL TECHNOLOGIES 116.700 € (+25,28 %)
CAPGEMINI 89.680 € (+1,33 %)
SHELL PLC 33.700 € (-1,00 %)
BUREAU VERITAS 26.120 € (+0,66 %)
HERMES INTL 1 626.000 € (+0,77 %)
PHILIPS KON 23.890 € (-0,17 %)
SANOFI 75.070 € (+1,78 %)
ASML HOLDING 1 578.200 € (-0,99 %)
BOLLORE 4.100 € (+0,15 %)
VEOLIA ENVIRON. 36.230 € (+0,22 %)
SMCP 5.015 € (+0,30 %)
FLOW TRADERS 25.580 € (-0,93 %)
ASM INTERNATIONAL 948.000 € (-4,34 %)
AYVENS 11.460 € (-0,87 %)
CSG 12.682 € (+2,69 %)
BE SEMICONDUCTOR 282.700 € (-2,21 %)
SCOR SE 31.980 € (+0,50 %)
STMICROELECTRONICS 62.580 € (-3,81 %)
ESSILORLUXOTTICA 168.650 € (+1,54 %)
CRCAM TOURAINE CCI 138.500 € (-0,93 %)
LISI 66.100 € (-0,15 %)
LVMH 495.750 € (+0,27 %)
BOUYGUES 49.750 € (-0,78 %)
DSM FIRMENICH AG 79.980 € (-0,65 %)
NEXANS 141.100 € (-3,75 %)
STELLANTIS NV 5.024 € (-1,95 %)
THALES 216.500 € (-0,87 %)
UMG 18.355 € (+0,71 %)
NN GROUP 76.320 € (-0,29 %)
AHOLD DEL 35.430 € (+0,85 %)
2CRSI 27.520 € (+8,01 %)
SODEXO 51.250 € (-0,10 %)
SOITEC 114.350 € (+1,87 %)
TKH GROUP 43.620 € (+1,73 %)
OVH 13.600 € (+1,49 %)
LNA SANTE 34.000 € (+3,03 %)
EUROFINS SCIENT. 68.960 € (+1,00 %)
BAM GROEP KON 12.550 € (-1,18 %)
AMG 32.900 € (-1,56 %)
CEGEDIM 11.040 € (-1,43 %)
AALBERTS NV 38.980 € (-1,66 %)
DANONE 72.120 € (+3,06 %)
ALSTOM 15.380 € (-1,94 %)
REXEL 36.860 € (-1,18 %)
RELX 27.440 € (-0,29 %)
HAFFNER ENERGY 0.217 € (-2,25 %)
ERAMET 45.160 € (-1,40 %)
SAINT GOBAIN 80.600 € (-1,42 %)
BNP PARIBAS ACT.A 101.120 € (-1,83 %)
RUBIS 31.540 € (+0,64 %)
PERNOD RICARD 65.960 € (-0,06 %)
JCDECAUX 19.050 € (+1,33 %)
SAVENCIA 66.600 € (0,00 %)
AIRBUS 191.900 € (-1,63 %)
ALTEN 53.400 € (+1,81 %) |
08/03/2023 14:00
Ra Med Electrophysiology Division Announces New Publication of Clinical DataNew Study Confirms Advantages of Using VIVO for Pre-Procedure Ventricular Ablation Planning FORT MILL, SC / ACCESSWIRE / March 8, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had new clinical data published for its leading product VIVO (View Into Ventricular Onset), that confirms the perceived benefits of using VIVO in a ventricular ablation program. VIVO is a non-invasive localization system that provides the physician with data about the patient's heart prior to a ventricular ablation. This data is then used by the physician to plan certain aspects of the procedure including where to look for the start of the arrhythmia (often the target for the ablation), which can be a time-consuming process. The newest publication (https://www.sciencedirect.com/science/article/pii/S0022073623000250) by the Royal Brompton Hospital (London, UK) with lead author Professor Sabine Ernst, confirms that VIVO does reduce mapping time by almost 30%. A reduction in mapping time leads to a total reduction in procedure time, potentially increasing patient safety. In addition, this publication discusses that patients with previous ablations that were unable to be performed were now able to have successful ablation procedures improving treatment options for patients with infrequent ventricular arrhythmias. "We have seen for some time that using VIVO would have many benefits," said David Jenkins, CEO. "It is great to have data that shows how pre-procedure planning with VIVO can provide benefits not just to patients by reducing their time under anesthesia, but also improving the workflow for physicians. VIVO has the potential to allow additional procedures in the EP labs due to increased efficiency and reduce the amount of patient backlog. VIVO is showing tremendous potential to improve workflows and outcomes that help patients, physicians and hospitals." Mr. Jenkins continued, "This publication joins a number of other publications and scientific presentations on the advantages of utilization of the VIVO technology within the hospital setting. Combined with almost 1,000 procedures performed to date with VIVO, the early experience is accelerating to what we believe will become widespread clinical acceptance and usage." About Ra Medical Systems Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. CONTACTS: At the Company SOURCE: Ra Medical Systems, Inc. View source version on accesswire.com: https://www.accesswire.com/742477/Ra-Med-Electrophysiology-Division-Announces-New-Publication-of-Clinical-Data Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière